Post Profile






Cabozantinib improves progression-free survival in metastatic renal cell carcinoma

Cabozantinib significantly improves progression-free survival and response rate in patients with metastatic renal cell carcinoma compared to sunitinib, according to research.
read more

share

Related Posts


Exelixis Initiates Phase 3 Pivotal Trial of Cabozantinib in Patients With Metastatic Renal Cell Carc

Business & Finance / Personal Finance : Savings Experiment

Exelixis Initiates Phase 3 Pivotal Trial of Cabozantinib in Patients With Metastatic Renal Cell Carcinoma SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. ( NAS: EXEL ) today announced it has initiated METEOR, a phase 3...

Scientists investigate potential markers for a response to sunitinib in patients with metastatic RCC

Academics / General Science : Science Codex

Milan, 18 March 2013 – Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumours might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), ac...

Axitinib Significantly Extended Progressionâ??Free Survival Compared With Sorafenib In Patients With Previously Treated Advanced Renal Cell Carcinoma

Health : Medical News Today

Pfizer today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma (RCC), axitinib significantly extended progressionâ??free survival (PFS) [HR=0.665,...

Sunitinib Benefits Patients with Renal Cell Carcinoma

Health : Newswise Medical News

Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some study results in animals.

In Patients With Metastatic Renal Cell Carcinoma Scientists Investigate Potential Markers For A Response To Sunitinib

Health : Medical News Today

Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumours might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a new study ...

Comments


Copyright © 2016 Regator, LLC